Immunological Approach for the Treatment of Alzheimer's Disease

Journal of Molecular Neuroscience

Volumn 20, Issue 3, 2003, Pages 283-286

  Solomon, Beka ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Alzheimer's disease; Immunotherapy; N terminal epitope

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; ARGININE; CHAPERONE; EPITOPE; GLUTAMIC ACID; HISTIDINE; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PEPTIDE; PHENYLALANINE; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; DRUG MECHANISM; IMMUNIZATION; IMMUNOPHARMACOLOGY; IMMUNOTHERAPY; IN VITRO STUDY; NEUROIMMUNOLOGY; NONHUMAN; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; SENILE PLAQUE; TRANSGENIC MOUSE; ANIMAL; BRAIN; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; MEMORY DISORDER; MOUSE; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE;

MUS MUSCULUS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BRAIN; DISEASE MODELS, ANIMAL; EPITOPES; MEMORY DISORDERS; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY; SENILE PLAQUES;

EID: 0642370868     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1385/JMN:20:3:283     Document Type: Article

References (22)

1. Bacskai B. J., Kajdasz S. T., Mclellan M. E., Games D., Seubert P., Schenk D., and Hyman B. T. (2002) Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy. J. Neurosci. 22, 7873-7878.
2. Bard F., Cannon C., Barbour R., Burke R.-L., Games D., Grajeda H., et al. (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916-920.
3. Blond S. and Goldberg M. (1987) Partly native epitopes are already present on early intermediates in the folding of tryptophan synthase. Proc. Natl. Acad. Sci. USA 84, 1147-1151.
4. Carlson J. D. and Yarmush M. L. (1992) Antibody assisted protein refolding. Biotechnology 10, 86-91.
5. Dobson C. M. (2002) Getting out of shape. Nature 418, 729-730.
6. Frauenfelder H., Petsko G. A., and Tsernoglou D. (1979) Temperature dependent X-ray diffraction as a probe of protein structural dynamics. Na ture 280, 558-563.
7. Frenkel D., Balass M., and Solomon B. (1998) N-Terminal EFRH sequence of Alzheimer's β-amyloid peptide represents the epitope of its anti-aggregating antibodies. J. Neuroimmunol. 88, 85-90.
8. Frenkel D. Balass M., Katchalski-Katzir E., and Solomon B. (1999) High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β-amyloid peptide is essential for modulation of fibrillar aggregation. J. Neuroimmunol. 95, 136-142.
9. Frenkel D., Katz O., and Solomon B. (2000) Immunization against Alzheimer's β-amyloid plaques via EFRH phageadministration. Proc. Natl. Acad. Sci. USA 97(21), 11,455-11,459.
10. Frenkel D., Kariv N., and Solomon B. (2001) Generation of auto-antibodies towards Alzheimer's disease vaccination. Vaccine 19, 2615-2619.
11. Frenkel D., Dewachter I., Van Leuven F., and Solomon B. (2003) Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization. Vaccine 21, 1060-1065.
12. Hanan E. and Solomon B. (1996) Protective effect of monoclonal antibodies against Alzheimer's β-amyloid aggregation. Amyloid Int. J. Exp. Clin. Invest. 3, 130-133.
13. Janus C, Pearson J., McLaurin J., Mathews P. M., Jiang Y., Schmidt S. D., et al. (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979-982.
14. Karplus M. and Petsko G. A. (1990) Molecular dynamics simulations in biology. Nature 347, 631-639.
15. Moechars D., Lorent K., De Strooper B., Dewachter I., and Van Leuven F. (1996) Expression in brain of amyloid precursor protein mutated in the alpha-secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice. EMBO J. 15, 1265-1274.
16. Morgan D., Diamond D. M., Gottschall P. E., Ugen K. E., Dickey C., Hardy J., et al. (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982-985.
17. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., et al. (1999) Immunization with amyloid-β attenuates Alzheimer'disease-like pathology in the PDAPP mouse. Nature 400, 173-177.
18. Sigurdsson E. M., Scholtzova H., Mehta P. D., Frangione B., and Wisniewski T. (2001) Immunization with a non-toxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am. J. Pathol. 159, 439-447.
19. Solomon B. and Schwartz F. (1995) Chaperone-like effect of monoclonal antibodies on refolding of heat-denatured carboxypeptidase A. J. Mol. Recognition 8, 72-76.
20. Solomon B., Koppel R., Hannan E., and Katzav T. (1996) Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer's β-amyloid peptide. Proc. Natl. Acad. Sci. USA 93, 452-455.
21. Solomon B., Koppel R., Frankel D., and Hanan-Aharon E. (1997) Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. USA 94, 4109-4112.
22. Solomon B., Taraboulos A., and Katchalsky Katzir E., eds. (2001) Conformational Diseases: A Compendium, Karger, Tunbridge Wells, UK, pp. 276-281.